$AFYA

Junior Lelio de Souza sold $623K of AFYA

Junior Lelio de Souza (Vice President) sold 41,541 shares of Afya Ltd (AFYA) at $15.00 ($0.62M total) on 2026-06-26.

Original reporting
SEC EDGAR · Junior Lelio de Souza
Published Jun 30, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AFYA
Neutral
medium confidence
Mentioned
$AFYA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AFYANeutralLow
01

Why it matters

The disclosed fact is the size and price of the insider’s open-market sale; it does not include new operational, financial, or regulatory information about Afya.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing notes no 10b5-1 plan; traders may still treat the sale as marginally more informative than a typical planned sale, but the article provides no additional context (e.g., tax, diversification, or follow-on buys).

Relevance 5/10Novelty 3/10Timing: Form 4 filed June 30; sale executed June 26

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Afya Ltd.

Company-level read

Ticker impact

$AFYANeutralMedium confidence
Context

Afya Ltd VP Junior Lelio de Souza sold 41,541 shares in an open-market transaction for about $623K, per Form 4 filed June 30.

Expected impact

Low near-term impact; any effect is likely short-lived unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is not tied to new company fundamentals, guidance, or regulatory/operational events in the text.

Market effects

No sector read-across; this is a single-company insider transaction with no stated operational change.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish expectations, especially without a stated negative catalyst.

Key entities

  • Afya Ltd

    Subject of the Form 4 insider transaction; VP sold 41,541 shares at $15.00/share.

  • Junior Lelio de Souza

    Vice President who executed the sale; holdings after transaction were 36,204 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AFYAHigh

JPMorgan upgrades Afya stock rating on merger synergies

JPMorgan upgraded Afya Ltd. (AFYA) to Overweight, citing merger synergies of R$1.8 billion and a premium higher education company. The price target was lowered to $19.00 from $21.00. Afya reported Q2 2026 revenue growth of 6% and H1 growth of 7%, with net income rising 14% in Q2 and 7% in H1. The company trades at a P/E ratio of 8 and a 23% free cash flow yield.

$AFYAMed

Afya and Yduqs Confirm Merger Talks of Brazil’s Education Giants

Afya and Yduqs, Brazil's largest medical-education network and education group, confirmed early-stage merger talks on 24 August 2026. Yduqs shares rose 12.1% in São Paulo, while Afya's shares in New York increased 0.77%. The companies' second-quarter financials showed contrasting performances, with Afya in a stronger position. No binding agreements or details have been finalized, and both companies emphasized the preliminary nature of the discussions.

$AFYAMedAI 8/10

Afya (AFYA) Q2 2026 Earnings Call Transcript

Afya (AFYA) reported Q2 2026 revenue of BRL 1.985 billion, up 7% YoY. Adjusted EBITDA rose 3% to BRL 918 million, while net income increased 7% to BRL 463 million. The company faces AI competition in clinical decision tools but is integrating AI into its iClinic platform. Management reaffirmed its full-year EBITDA guidance of BRL 1.7-1.8 billion.